Close Menu

NEW YORK (GenomeWeb) – Canadian firm GenePOC recently expanded its staff and intends to enter the molecular diagnostics market with a Group B Streptococcus assay at the end of the second quarter of 2016 and a Clostridium difficile assay in Q4 2016.

The company will initially launch the tests as CE-IVD products in Europe, and is aiming for US Food and Drug Administration approval of its platform and assays in late 2016.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Atlantic reports another SARS-CoV-2 testing problem may be lurking: backlogs.

Researchers have sequenced the genome of "the Methuselah of freshwater fish."

The US Biomedical Advanced Research and Development Authority is supporting efforts to develop vaccines against SARS-CoV-2.

In Genome Biology this week: difference in methylation in neurons from Parkinson's disease patients, differential expression analysis by barcoded sequencing approach, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.